KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Consolidated Earnings Guidance for the First Half of Fiscal Year 2018 and Year Ending March 31, 2018; Provides Second Quarter and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2018
July 30, 2017
Share
KYORIN Holdings, Inc. reported consolidated earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported net sales of JPY 26,458 million against JPY 27,707 million a year ago. Operating income was JPY 2,595 million against JPY 3,244 million a year ago. Ordinary income was JPY 2,805 million against JPY 3,485 million a year ago. Profit attributable to owners of parent was JPY 2,393 million against JPY 2,580 million a year ago. Net income per share was JPY 32.54 against JPY 35.15 a year ago.
For the first half of fiscal year 2018, the company expects consolidated net sales of JPY 54,600 million, operating income of JPY 5,300 million, ordinary income of JPY 5,600 million, and profit attributable to owners of parent of JPY 4,500 million or JPY 61.21 per share.
For the year ending March 31, 2018, the company expects consolidated net sales of JPY 113,400 million, operating income of JPY 12,100 million, ordinary income of JPY 12,600 million, and profit attributable to owners of parent of JPY 9,700 million or JPY 131.94 per share.
The company expects second quarter dividend of JPY 20.00 per share for the fiscal year ending March 31, 2018.
The company expects year-end dividend of JPY 38.00 per share for the fiscal year ending March 31, 2018.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Consolidated Earnings Guidance for the First Half of Fiscal Year 2018 and Year Ending March 31, 2018; Provides Second Quarter and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2018
KYORIN PHARMACEUTICAL CO., LTD. 
